FDA Updates Eligibility for Solid Tumor Immunotherapy

Adults with advanced tumors now need a higher mutation threshold to qualify for these specific immunotherapy treatments.

Updated on Oct. 22, 2026 in Cancer

Isometric editorial illustration showing stylized hexagonal protein structures in deep teal and oxblood, representing cell-level immunotherapy interaction. — The FDA updated the threshold for TMB-H solid tumor immunotherapy to 13 mutations per megabase to ensure clinical efficacy for patients. AI Illustration. Upload story photo >

Live Poll

Should the FDA require higher efficacy thresholds for cancer drugs before granting final approval?

The FDA has granted traditional approval for pembrolizumab and its combination with berahyaluronidase alfa-pmph to treat adults with unresectable or metastatic solid tumors that are tumor mutational burden-high (TMB-H). This updated indication now requires a threshold of 13 or more mutations per megabase to qualify for treatment.

Why it matters

The FDA adjusted the TMB-H threshold to 13 mutations per megabase because clinical efficacy was not confirmed for patients with tumors falling between 10 and 13 mutations. This change refines which patients with advanced cancer may benefit from this immunotherapy-based approach after exhausting other options.

In a pooled analysis of 220 patients from the KEYNOTE-158 trial, the FDA evaluated the efficacy of this immunotherapy regimen for solid tumors. The evidence showed an objective response rate of 36 percent, with more than half of those responders maintaining the effect for at least 12 months.

The players

FDA

The federal agency responsible for protecting public health by ensuring the safety and efficacy of human drugs and biological products.

The details

Pembrolizumab is a monoclonal antibody that targets the PD-1 protein, effectively removing the 'brake' on the immune system to help T-cells identify and attack cancer cells. In cases where the treatment is paired with berahyaluronidase alfa-pmph, the additive enzyme helps improve the delivery of the drug into the tissue by locally degrading hyaluronan. This mechanism is specifically targeted at tumors that exhibit a high number of mutations, as these genetic variations produce more neoantigens that the immune system can detect.

October 16, 2026: The FDA granted traditional approval for the therapies.

Health Landscape

This decision represents a narrowing of the diagnostic criteria for immunotherapy eligibility based on recent data from the KEYNOTE-158 trial. It reflects a broader shift toward using precise genomic markers like TMB to predict which patients are most likely to respond to checkpoint inhibitors.

Patients currently being evaluated for immunotherapy should clarify with their oncology team if their tumor mutational burden meets the updated 13 mutations per megabase threshold. It is also important to discuss whether all other satisfactory alternative treatment options have been exhausted.

The takeaway

The FDA has formalized a higher genetic threshold for using specific immunotherapy treatments in advanced solid tumors. If you are managing metastatic cancer, ask your oncologist if molecular profiling of your tumor is indicated and how recent regulatory changes might impact your eligibility.